Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 18/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.39 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.39 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.39 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.39 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.39 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.39 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.39 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.39 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.39 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.39 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.39 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.39 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.39 |
| ▸ | PSMA8 | Q8TAA3 | 2/20 | 0.39 |
| ▸ | PSMB7 | Q99436 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26257809 | 0.77 | PSMB5 (0.44) | PSMB5PSMB8ANPEPPSMB1PSMB11 | |
| SCHEMBL21709722 | 0.73 | PSMB5 (0.46) | PSMB5PSMB8ANPEPPSMB1PSMB11 | |
| SCHEMBL10952773 | 0.70 | PSMB5 (0.56) | PSMB5PSMB8PSMB1PSMB11PSMA7 | |
| SCHEMBL22149328 | 0.70 | PSMB5 (0.43) | PSMB5PSMB8ANPEPPSMB1PSMB11 | |
| SCHEMBL21558113 | 0.69 | PSMB5 (0.54) | PSMB5PSMB8PSMB1PSMB11PSMA7 | |
| SCHEMBL12340799 | 0.66 | DPP4 (0.57) | PSMB5PSMB8ANPEPPSMB1PSMB11 | |
| SCHEMBL12340797 | 0.66 | DPP8 (0.62) | PSMB5PSMB8PSMB1PSMB11PSMA7 | |
| SCHEMBL12340810 | 0.66 | PSMB5 (0.44) | PSMB5PSMB8ANPEPPSMB1PSMB11 | |
| SCHEMBL12340807 | 0.66 | PSMB5 (0.60) | PSMB5PSMB8PSMB1PSMB11PSMA7 | |
| SCHEMBL10951919 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | claimed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | claimed |
| EP-2265267-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NovaBay Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| WO-2010124237-A1 | METHODS OF TREATING INFECTIONS OF THE NAIL | NOVABAY PHARMACEUTICALS INC. (US) | 2010-10-28 | — | — | WO | claimed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | claimed |
| WO-2009126912-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| EP-1896001-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2006081392-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | claimed |
| EP-2265267-B1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | GOTTARDI WALDEMAR (AT) | 2016-09-21 | — | — | EP | disclosed |
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | disclosed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| EP-2312939-A1 | ANTIMICROBIAL GEL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2265267-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NovaBay Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010019723-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010017405-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009126912-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1896001-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | NOVABAY PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | disclosed |
| WO-2006081392-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | POLR1C, TYR, NACA | PSMB5 1981/4885PSMB8 1922/4885ANPEP 223/4885 |
| US-20140227201-A1 | Antimicrobial Gel Formulations | CUTA, TUBA3C, POLR1C | PSMB5 4412/4885PSMB8 3759/4885ANPEP 1998/4885 |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | CFTR, NAT1, ELANE | PSMB5 1720/4885PSMB8 2361/4885ANPEP 75/4885 |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | CUTA, TUBA3C, POLR1C | PSMB5 4412/4885PSMB8 3759/4885ANPEP 1998/4885 |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | DAO, ASNS, DDC | PSMB5 1224/4885PSMB8 1705/4885ANPEP 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.